Tech Company Financing Transactions
Appia Bio Funding Round
Appia Bio closed a $52 million Series A funding round on 5/12/2021. Investors included 8VC, FreeFlow and Sherpa Capital.
Transaction Overview
Company Name
Announced On
5/12/2021
Transaction Type
Venture Equity
Amount
$52,000,000
Round
Series A
Investors
8VC (Lead Investor) (David Moskowitz)
Proceeds Purpose
Proceeds from the financing will support the advancement of Appia Bio's pipeline of allogeneic CAR-iNKT cell therapy candidates into the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
570 Westwood Plaza
Los Angeles, CA 90095
USA
Los Angeles, CA 90095
USA
Phone
Undisclosed
Website
Email Address
Overview
Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
David Baltimore
Chief Executive Officer
JJ Kang
Chief Medical Officer
Jeffrey Wiezorek
Chief Operating Officer
Edmund Kim
Browse more venture capital transactions:
Prev: 5/12/2021: parcelLab venture capital transaction
Next: 5/12/2021: CognitOps venture capital transaction
Share this article
About Our VC Transactions Data
We record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs